FDA authorizes 3rd COVID vaccine dose for immunocompromised individuals
The U.S. Food and Drug Administration (FDA) has amended the emergency use authorizations for both the Pfizer-BioNTech and Moderna COVID-19 vaccines. Read More
Novavax COVID-19 vaccine booster appears effective after primary vaccination
Novavax announced preliminary data indicating that a single booster dose of the company's recombinant nanoparticle protein-based COVID-19 vaccine drew a 4.6-fold increase in functional antibody titers. Read More
Sanofi to acquire mRNA partner Translate Bio for $3.2B
Sanofi is set to acquire COVID-19 development partner Translate Bio for $3.2 billion, a deal that will bring an mRNA platform, as well as an early stage pipeline in rare pulmonary diseases, into Sanofi's portfolio. Read More
Scientists visualize viruses in motion using advanced electron microscopy
Advanced electron microscopy has enabled researchers to visualize how human viruses move in high resolution in a near-native environment. The visualization technique, published in Advanced Materials on July 24, could lead to an improved understanding of the molecular mechanisms of vaccines and therapeutics. Read More
EMA takes positive stance on Moderna COVID-19 vaccine for adolescents
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use has taken a positive position on marketing authorization for Moderna's COVID-19 vaccine for use in adolescents 12 years of age and older. Read More
Machine learning predicts if a COVID-19 clinical trial will be successful
Using machine learning, researchers have teased out the underlying factors of success for COVID-19 clinical trials, according to a PLOS One article published on July 12. The analysis showed that drug features and study keywords are the most informative features of COVID-19 trials. Read More
Africa to get doses of Pfizer-BioNTech COVID-19 vaccine
Pfizer and BioNTech have signed a letter of intent with South Africa-based Biovac Institute to manufacture and distribute the companies' COVID-19 vaccine within the African Union. Read More
Tetherex licenses adenovirus vaccine platform from Mayo Clinic
Tetherex Pharmaceuticals has obtained an exclusive worldwide license for the development and commercialization of a novel single-cycle adenovirus vaccine platform from the Mayo Clinic. The platform will be used to target multiple infectious diseases beginning with a COVID-19 vaccine. Read More
With Hitachi deal done, Fujifilm sets sights on healthcare growth
Fresh off its acquisition of Hitachi's medical imaging business, Japanese industrial giant Fujifilm on July 1 rebranded its healthcare subsidiaries in the U.S. and Europe to reflect the newly integrated company. The deal exemplifies Fujifilm's plan to make healthcare its primary business. Read More
Cenexi to manufacture OSE's COVID-19 vaccine
Cenexi signed a deal agreeing to manufacture clinical batches of CoVepiT, OSE Immunotherapeutics' COVID-19 vaccine candidate, which will be used in the product's development phases. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter